“…We report that MSCs from different sources can be forcedly infected with a HER2-retargeted oncolytic HSV. Progeny virus spread from MSCs to cancer cells in vitro and in vivo. …”
Enlace del recurso
Enlace del recurso

“…We have created a novel fluorescent model of a human ovarian carcinoma xenograft overexpressing receptor HER2, a promising molecular target of solid tumors. …”
Enlace del recurso
Enlace del recurso

“…However, not all cases of HER2-positive breast tumours derive similar benefit from HER2-directed therapy, and a significant number of patients experience disease progression because of primary or acquired resistance to anti-HER2-directed therapies. …”
Enlace del recurso
Enlace del recurso

“…Previously, we demonstrated that silencing E2F1 or E2F3 suppresses centrosome amplification (CA) and chromosome instability (CIN) in Her2(+) breast cancer cells without markedly altering proliferation. …”
Enlace del recurso
Enlace del recurso

“…Our results suggest that activation of STAT3 may play an important role in the acquisition of resistance to gemcitabine and HER inhibitors in pancreatic cancer and warrant further studies on the therapeutic potential of STAT3 inhibitors in such a setting.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…OBJECTIVE: We aimed to compare serum and urinary HER2/neu levels between healthy control group and patients with non-muscle invasive bladder cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Within PrefHer (NCT01401166), patients and healthcare professionals (HCPs) preferred subcutaneous (SC) over intravenous (IV) trastuzumab. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The epidermal growth factor receptor (EGFR) and a co-receptor denoted HER2/ERBB2, are frequently overexpressed or mutated in solid tumors, such as carcinomas and gliomas. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Stability, small size, and efficacy of DARPins allowed the generation of MVs simultaneously targeted to tumor marker HER2/neu and cancer stem cell (CSC) marker EpCAM. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Evaluating HER2 gene amplification is an essential component of therapeutic decision-making for advanced or metastatic gastric cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The aim of this study was to investigate the impact of BCSC marker expression on clinical outcome and trastuzumab response in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. METHODS: We analysed the expression of BCSC markers, CD44+/CD24− and aldehyde dehydrogenase 1 (ALDH1), and clinical outcomes in three sets of breast cancer cases: Set 1, 242 HER2-positive primary breast cancers treated by various modalities; Set 2, 447 HER2-positive primary breast cancers treated with surgery and chemotherapy plus adjuvant trastuzumab; Set 3, 112 metastatic HER2-positive breast cancers treated with trastuzumab. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The present study aimed to investigate the expression of human epidermal growth factor receptors (HERs) (HER1/HER2/HER3/HER4) and their phosphorylated forms (p-HER1/p-HER2/p-HER3/p-HER4) in pulmonary carcinoids (PCs). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Numerous original clinical studies have attempted to investigate the prognostic value of HER-2 overexpression in osteosarcoma, but the results of these studies are not consistent. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…OBJECTIVE(S): Expression of HER2 in gastric carcinoma has direct prognostic and therapeutic implications in patient management. …”
Enlace del recurso
Enlace del recurso

“…Moreover, AKT1(E17K) prevents HER2-driven mammary tumor formation, in part through negative feedback inhibition of RTK signaling. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Human epidermal growth factor receptor 2 (HER2)-targeted agents are an effective approach to treating HER2-positive breast cancer patients. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Pathological complete remission (pCR) of estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer is rarely achieved after neoadjuvant chemotherapy (NAC). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Of 47,123 women included, 33.1% (10,712/32,376) of HR+/HER2−, 33.1% (1912/5768) of HR+/HER2+, 29.6% (850/2875) of HR−/HER2+, and 27.7% (1689/6104) of triple negative breast cancer patients received immediate breast reconstruction (chi-square test, P < 0.001), respectively. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We investigated the clinical implications of single hormone receptor negativity in a luminal B HER2-negative group. METHODS: We collected luminal B HER2-negative breast cancer data that were estrogen receptor (ER) and/or progesterone receptor (PR) positive, Ki 67 high (>14 %), and HER2 negative and divided them into the ER- and PR-positive group and the ER- or PR-negative group. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: To investigate whether very low mammographic breast density (VLD), HER2, and hormone receptor status holds any prognostic significance within the different prognostic categories of the widely used Nottingham Prognostic Index (NPI). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso